Some clever autism researchers pin their hopes on genetics, while some equally clever ones are not convinced.
One big problem is that genetic testing is still not very rigorous, it is fine if you know what you are looking for, like a specific single gene defect, but if it is a case of find any possible defect in any of the 700+ autism genes it can be hopeless.
Most of the single gene types of autism can be diagnosed based on known physical differences and then that specific gene can be analyzed to confirm the diagnosis.
Today’s post includes some recent examples from the research, and they highlight what is often lacking - some common sense.
There are numerous known single gene conditions that lead to a cascade of dysfunctions that can result in behaviors people associate with autism. However in most of these single gene conditions, like Fragile X or Pitt-Hopkins, there is a wide spectrum, from mildly affected to severely affected.
There are various different ways in which a gene can be disturbed and so within a single gene condition there can be a variety of sub-dysfunctions. A perfect example was recently forwarded to me, a study showing how a partial deletion of the Pitt Hopkins gene (TCF4) produced no physical features of the syndrome, but did unfortunately produce intellectual disability.
The study goes on to suggest that “screening for mutations in TCF4 could be considered in the investigation of NSID (non-syndromic intellectual disability)”
Partial deletion of TCF4 in three generation family with non-syndromic intellectual disability, without features of Pitt-Hopkins syndrome
This all matters because one day when therapies for Pitt Hopkins are available, they would very likely be effective on the cognitive impairment of those with undiagnosed partial-Pitt Hopkins.
Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.
But isn’t that Tuberous sclerosis (TSC) extremely rare? like Pitt Hopkins. Is it really relevant?
Tuberous sclerosis (TSC) is indeed a rare multisystem genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin. A combination of symptoms may include seizures, intellectual disability, developmental delay, behavioral problems, skin abnormalities, and lung and kidney disease. TSC is caused by a mutation of either of two genes, TSC1 and TSC2,
About 60% of people with TSC have autism (biased to TSC2 mutations) and many have epilepsy.
How rare is TSC? According to research between seven and 12 cases per 100,000, with more than half of these cases undetected.
Call it 0.01%, rare indeed.
How rare is partial TSC? What is partial TSC? That is just my name for what happens when you have just a minor missense mutation, you have a mutation in TSC2 but have none of the characteristic traits of tuberous sclerosis, except autism.
In a recent study of children with autism 20% has a missense mutation of TSC2.
Not so rare after all.
Mutations in tuberous sclerosis gene may be rife in autism
Mutations in TSC2, a gene typically associated with a syndrome called tuberous sclerosis, are found in many children with autism, suggests a genetic analysis presented yesterday at the 2016 International Meeting for Autism Research in Baltimore.
The findings support the theory that autism results from multiple ‘hits’ to the genome.
Tuberous sclerosis is characterized by benign tumors and skin growths called macules. Autism symptoms show up in about half of all people with tuberous sclerosis, perhaps due to abnormal wiring of neurons in the brain. Tuberous sclerosis is thought to result from mutations in either of two genes: TSC1 or TSC2.
The new analysis finds that mutations in TSC2 can also be silent, as far as symptoms of the syndrome go: Researchers found the missense mutations in 18 of 87 people with autism, none of whom have any of the characteristic traits of tuberous sclerosis.
“They had no macules, no seizure history,” says senior researcher Louisa Kalsner, assistant professor of pediatrics and neurology at the University of Connecticut School of Medicine in Farmington, who presented the results. “We were surprised.”
The researchers stumbled across the finding while searching for genetic variants that could account for signs of autism in children with no known cause of the condition. They performed genetic testing on blood samples from 87 children with autism.
Combined risk:
To see whether silent TSC2 mutations are equally prevalent in the general population, the researchers scanned data from 53,599 people in the Exome Aggregation Consortium database. They found the mutation in 10 percent of the individuals.
The researchers looked more closely at the children with autism, comparing the 18 children who have the mutation with the 69 who do not.
Children with TSC2 mutations were diagnosed about 10 months earlier than those without a mutation, suggesting the TSC2 mutations increase the severity of autism features. But in her small sample, Kalsner says, the groups show no differences in autism severity or cognitive skills. The researchers also found that 6 of the 18 children with TSC2 mutations are girls, compared with 12 of 69 children who don’t have the mutation.
TSC2 variants may combine with other genetic variants to increase the risk of autism. “We don’t think TSC is the sole cause of autism in these kids, but there’s a significant chance that it increases their risk,” Kalsner says.
"hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) is a consequence of tuberous sclerosis complex (TSC) 1/2 inactivation."
"the combination of rapamycin and resveratrol may be an effective clinical strategy for treatment of diseases with mTORC1 hyperactivation."
"the combination of rapamycin and resveratrol may be an effective clinical strategy for treatment of diseases with mTORC1 hyperactivation."
So for the 20% of autism with partial TSC, so-called Rapalogs and other mTOR inhibitors could be helpful, but Rapalogs all have side effects.
One interesting option that arose in my earlier post on Type 3 diabetes and intranasal insulin is Metformin. The common drug used for type 2 diabetes.
Metformin regulates mTORC1 signaling (but so does insulin).
'Metformin activates AMPK by inhibiting oxidative phosphorylation, which in turn negatively regulates mTORC1 signaling via activation of TSC2 and inhibitory phosphorylation of raptor. In parallel, metformin inhibits mTORC1 signaling by suppressing the activity of the Rag GTPases and upregulating REDD1."
Source: Rapalogs and mTOR inhibitors as anti-aging therapeutics
Clearly you could also just use intranasal insulin. It might be less potent but should have less side effects because it acting only within the CNS (Metfornin would be given orally).
The Shank protein and the Wnt protein family
Mutations in a gene called Shank3 occur in about 0.5 percent of people with autism.
But what about partial Shank3 dysfunction?
But what about partial Shank3 dysfunction?
Shank proteins also play a role in synapse formation and dendritic spine maturation.
Mutations in this gene are associated with autism spectrum disorder. This gene is often missing in patients with 22q13.3 deletion syndrome
Researchers at MIT have just shown, for the first time, that loss of Shank3 affects a well-known set of proteins that comprise the Wnt signaling pathway. Without Shank3, Wnt signaling is impaired and the synapses do not fully mature.
“The finding raises the possibility of treating autism with drugs that promote Wnt signaling, if the same connection is found in humans”
I have news for MIT, people already do use drugs that promote Wnt signaling, FRAX486 and Ivermectin for example. All without any genetic testing, most likely.
Reactivating Shank3, or just promote Wnt signaling
The study below showed that in mice, aspects of autism were reversible by reactivating the Shank3 gene. You might expect that in humans with a partial Shank3 dysfunction you might jump forward to the Wnt signaling pathway and intervene there.
Mouse study offers promise of reversing autism symptoms
One reader of this blog finds FRAX486 very helpful and to be without harmful side effects. FRAX 486 was recently acquired by Roche and is sitting over there on a shelf gathering dust.
Where from here?
I think we should continue to look at the single gene syndromes but realize that very many more people may be partially affected by them.
Today’s genetic testing gives many false negatives, unless people know what they are looking for; so many dysfunctions go unnoticed.
This area of science is far from mature and there may be many things undetected in the 97% of the genome that is usually ignored that affect expression of the 3% that is the exome.
This area of science is far from mature and there may be many things undetected in the 97% of the genome that is usually ignored that affect expression of the 3% that is the exome.
So best not to expect all the answers, just yet, from genetic testing; maybe in another 50 years.
Understanding and treating multiple-hit-autism, which is the majority of all autism, will require more detailed consideration of which signaling pathways have been disturbed by these hits. There are 700 autism genes but there a far fewer signaling pathways, so it is not a gargantuan task. For now a few people are figuring this out at home. Good for them.
I hope someone does trials of metformin and intranasal insulin in autism. Intranasal insulin looks very interesting and I was surprised to see in those earlier posts is apparently without side effects.
The odd thing is that metformin is indeed being trialed in autism, but not for its effect on autism, but its possible effect in countering the obesity caused by the usual psychiatric drugs widely prescribed in the US to people with autism.
My suggestion would be to ban the use of drugs like Risperdal, Abilify, Seroquel, Zyprexa etc.
Vanderbilt enrolling children with autism in medication-related weight gain study
Here are details of the trial.
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) (MET)
Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
